Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan
dc.contributor.author | Saito, Akiko M. | en_US |
dc.contributor.author | Kami, Masahiro | en_US |
dc.contributor.author | Mori, Shin-Ichiro | en_US |
dc.contributor.author | Kanda, Yoshinobu | en_US |
dc.contributor.author | Suzuki, Ritsuro | en_US |
dc.contributor.author | Mineishi, Shin | en_US |
dc.contributor.author | Takami, Akiyoshi | en_US |
dc.contributor.author | Taniguchi, Shuichi | en_US |
dc.contributor.author | Takemoto, Yoshinobu | en_US |
dc.contributor.author | Hara, Masamichi | en_US |
dc.contributor.author | Yamaguchi, Masaki | en_US |
dc.contributor.author | Hino, Masayuki | en_US |
dc.contributor.author | Yoshida, Takashi | en_US |
dc.contributor.author | Kim, Sung-Won | en_US |
dc.contributor.author | Hori, Akiko | en_US |
dc.contributor.author | Ohashi, Yasuo | en_US |
dc.contributor.author | Takaue, Yoichi | en_US |
dc.date.accessioned | 2007-09-20T19:03:25Z | |
dc.date.available | 2008-11-05T15:05:43Z | en_US |
dc.date.issued | 2007-10 | en_US |
dc.identifier.citation | Saito, Akiko M.; Kami, Masahiro; Mori, Shin-Ichiro; Kanda, Yoshinobu; Suzuki, Ritsuro; Mineishi, Shin; Takami, Akiyoshi; Taniguchi, Shuichi; Takemoto, Yoshinobu; Hara, Masamichi; Yamaguchi, Masaki; Hino, Masayuki; Yoshida, Takashi; Kim, Sung-Won; Hori, Akiko; Ohashi, Yasuo; Takaue, Yoichi (2007)."Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan." American Journal of Hematology 82(10): 873-880. <http://hdl.handle.net/2027.42/56131> | en_US |
dc.identifier.issn | 0361-8609 | en_US |
dc.identifier.issn | 1096-8652 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/56131 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17570513&dopt=citation | |
dc.description.abstract | This prospective trial assessed the safety and efficacy of allogeneic hematopoietic stem cell transplantation from a HLA-matched donor with a reduced-intensity regimen (RIST) consisting of iv fludarabine 30 mg/m 2 for 6 days and oral busulfan 4 mg/kg/day for 2 days in patients older than 50 years with hematological malignancies. Cyclosporine alone or cyclosporine with short-term methotrexate was randomized for graft-versus-host disease prophylaxis. After 30 patients had been enrolled, an interim analysis was performed, and this report focuses on a precise evaluation of the toxicity profile and chimerism kinetics. Sustained engraftment in all patients, no severe regimen-related toxicity (RRT) within 20 days, and no transplant-related mortality through Day 100 were observed. T-cell (CD3+) full-donor (over 90%) chimerism was observed in 22 of the 30 patients, while the remaining eight had mixed-donor chimerism over 77% on Day 90. Thereafter, five subsequently converted to full-donor chimerism without donor lymphocyte infusion by day 120 ( n = 4) or Day 180 ( n = 1). Two showed persistent mixed chimerism without relapse through Day 180. Grade III–IV acute graft-versus-host disease and extensive chronic graft-versus-host disease occurred in 10% and 73%, respectively. With a median follow-up of 1.5 years, overall survival and disease-free survival at 1 year was 83% and 62%, respectively. Seven patients hematologically relapsed overall, and five of them had myelodysplastic syndrome with poor prognostic factors. In older patients, RIST with fludarabine and busulfan was associated with acceptable toxicities and a satisfactory antileukemia effect, regardless of the early chimerism status. Am. J. Hematol. 82:873–880, 2007. © 2007 Wiley-Liss, Inc. | en_US |
dc.format.extent | 169974 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan ; Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan ; Dana-Farber Cancer Institute, 44 Binney Street, SM 275 Boston, MA 02115 | en_US |
dc.contributor.affiliationother | Division of Exploratory Research, Institution of Medical Science, The University of Tokyo, Tokyo, Japan | en_US |
dc.contributor.affiliationother | Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan | en_US |
dc.contributor.affiliationother | Department of Cell Therapy and Transplantation Medicine, University of Tokyo Hospital, Tokyo, Japan | en_US |
dc.contributor.affiliationother | Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya, Japan | en_US |
dc.contributor.affiliationother | Department of Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Ishikawa, Japan | en_US |
dc.contributor.affiliationother | Department of Hematology, Toranomon Hospital, Tokyo, Japan | en_US |
dc.contributor.affiliationother | Medical Corporation Kouryokai CPC Clinic, Kagoshima, Japan | en_US |
dc.contributor.affiliationother | Division of Hematology, Ehime Prefectural Central Hospital, Ehime, Japan | en_US |
dc.contributor.affiliationother | Department of Hematology and Immunology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan | en_US |
dc.contributor.affiliationother | Department of Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Osaka, Japan | en_US |
dc.contributor.affiliationother | Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan | en_US |
dc.contributor.affiliationother | Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan | en_US |
dc.contributor.affiliationother | Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan | en_US |
dc.contributor.affiliationother | Department of Biostatistics/Epidemiology and Preventive Health Sciences, School of Health Sciences and Nursing, University of Tokyo, Tokyo, Japan | en_US |
dc.contributor.affiliationother | Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan | en_US |
dc.identifier.pmid | 17570513 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/56131/1/20977_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/ajh.20977 | en_US |
dc.identifier.source | American Journal of Hematology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.